Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
December 17, 2020 07:00 ET
|
Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing testsA single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to...
Otonomy Provides Business Update Related to COVID-19 Pandemic
April 09, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Provides Corporate and Product Pipeline Update
January 09, 2020 07:30 ET
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 05, 2019 16:13 ET
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration...
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
September 17, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...